Wholeheartedly agree with your post. PIQ have been ticking the boxes. According to the ANN, there are 260,000 CLIA accredited laboratories in the USA, the majority of which have the capability of using PromarkerD with dual technologies. That’s the beauty of this, even if they don’t have mass spectrometry they are still able to utilise the ELISA test kit & have analysis done remotely. For me that’s a no brainer, not just in the USA.
it’s not like big laboratories don’t take M&A seriously. NASH is another disease on the rise:
New drugs coming out for Endometriosis pain in the USA, another unmet clinical need PIQ are developing a test for & diagnosed by laporotomy & suspected on clinical symptoms. When this test in our pipeline is up & running, I think it will be huge & possibly may prevent exploratory surgery...there’s always a risk with anaesthetics & surgery...& early diagnosis means earlier treatment & possibly prevent infertility in younger women. 1:10 here in Australia.
Whilst we have standard diabetes & kidney testing available, there is nothing that is going to predict it apart from PromarkerD, so yes a little too late when blood & urine tests are showing up as abnormal, especially in younger people, which is a damn shame.
Hopefully some of the bigger players can see the value in this, as obviously we both do. Clinical Trials included, not just diagnostics.
PIQ Price at posting:
31.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)